Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS, Thelemann T, Klar R, Kallert SM, Festag J, Buchi M, Hinterwimmer L, Schell M, Michel S, Jaschinski F, Zippelius A. Kashyap AS, et al. Among authors: klar r. J Immunother Cancer. 2019 Mar 12;7(1):67. doi: 10.1186/s40425-019-0545-9. J Immunother Cancer. 2019. PMID: 30871609 Free PMC article.
ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.
Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, Cubillos-Ruiz JR, Munn DH, Conejo-Garcia JR, Rodriguez PC. Cao Y, et al. Among authors: klar r. Nat Commun. 2019 Mar 20;10(1):1280. doi: 10.1038/s41467-019-09263-1. Nat Commun. 2019. PMID: 30894532 Free PMC article.
Publisher Correction: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.
Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, Cubillos-Ruiz JR, Munn DH, Conejo-Garcia JR, Rodriguez PC. Cao Y, et al. Among authors: klar r. Nat Commun. 2019 Aug 15;10(1):3680. doi: 10.1038/s41467-019-11563-5. Nat Commun. 2019. PMID: 31417079 Free PMC article.
A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R, Michel S, Schell M, Hinterwimmer L, Zippelius A, Jaschinski F. Klar R, et al. Cancer Immunol Immunother. 2020 Jan;69(1):57-67. doi: 10.1007/s00262-019-02438-1. Epub 2019 Dec 4. Cancer Immunol Immunother. 2020. PMID: 31802183 Free PMC article.
147 results